Abstract Cyclophosphamide (CYC) has long been considered a gold standard in inducing renal remission and preventing renal flares for patients with systemic lupus erythematosus (SLE). However, the rational use of CYC has not reached a consensus, such as the timing and length of treatment, the route of administration, and the ideal dosage. The objective of this study was to assess the efficacy and safety of short-interval lower-dose (SILD) intravenous (IV) CYC in the treatment of SLE. A total of 225 patients with lupus nephritis were randomly assigned to a 1-year trial, either the SILD group (12 fortnightly pulses at a fixed dose of 400 mg followed by 6 monthly pulses) or high-dose (HD) group (6 monthly pulses followed by two quarterly pulses at a dose of 0.5~1.0 g/m 2 ). At 6 months of treatment, 28 % (30/107) of patients in the SILD group reached a complete remission (CR), and 51.4 % (55/107) were in partial remission (PR), as compared with 32.7 % (35/107) and 45.8 % (49/107) in the HD group, respectively. Serum albumin, 24-h urinary protein, and the scores of disease activity were significantly improved in both groups at 6 months and maintained at the end of clinical trial. However, the SILD group showed much less menstrual disturbances (11.5 %), gastrointestinal adverse effects (5.3 %), and leukopenia (9.7 %) than the HD group (28.6, 26.8, and 19.8 %, respectively) at the end of clinical trial. The efficacy of the short-interval lower-dose (SILD) IV CYC regimen in the treatment of lupus nephritis is equivalent to that of the high-dose (HD) regimen, whereas the incidence of adverse events is much lower in the SILD group.
Introduction
Systemic lupus erythematosus (SLE) is a complicated autoimmune disease with a diversity of clinical features, courses, and prognosis. Among the various organs affected in SLE, the kidney appears to be one of the most common, and at the same time, a more serious complication. Up to two thirds of patients with SLE have renal diseases at some stage of their illness. The risk of progression to end-stage renal failure in lupus nephritis (LN) is 10-15 % [1] . The therapeutic goals for LN are preserving renal function by initially inducing remission of nephritis and then preventing subsequent renal flares.
Cyclophosphamide (CYC) remains the "gold standard" treatment for severe organ-threatening SLE, especially when the renal and central nervous system functions are severely compromised. In the 1970s, Donadio et al. showed that SLE patients with proliferative nephritis who received steroids combined with oral administration of CYC were more likely to have a stable renal function than those treated with prednisone alone [2] . High-dose intravenous (IV) CYC in combination with glucocorticoids has become the standard routine therapy of LN, which has dramatically improved the prognosis. However, the adverse effects, including infection, bone marrow suppression, and gonadal toxicity, have limited the long-term use of this therapeutic regimen. Patients are increasingly reluctant to take such risks. Lower-dose IV CYC (0.5 g as a fixed dosage) regimen-as proposed by the Euro-Lupus Nephritis Trial-has been demonstrated to be efficacious. In addition, the rate of severe adverse events was much lower [3] . However, both regimens present a high relapse rate, and some patients fail to respond to the treatment [4, 5] . These phenomena probably attributed to the longer interval of the high-dose IV CYC regimen or the shorter duration of the lower-dose regimen (only 3 months). Moreover, due to the high costs of mycophenolate mofetil, IV CYC still holds on to a dominant position of induction and maintenance therapy for LN. This prompted us to find an ideal dosage and duration for IV CYC treatment in this study.
We hypothesized that short interval with prolonged exposure of lower-dose CYC (12 fortnightly IV CYC pulses at a fixed dose of 400 mg for 6 months and followed by 6 monthly pulses) may be beneficial to those refractory patients.
Patients and methods
The study was approved by the Ethics Committee of Peking University People's Hospital (FWA00001384). All study subjects signed the informed consent agreement.
Patients
Two hundred twenty-five patients with LN were enrolled from January 2004 to June 2012. All patients had met the following study criteria: (1) a definite diagnosis of SLE according to the 1997 American College of Rheumatology (ACR) criteria [6] , (2) female, (3) age ≥16 years old, (4) biopsy-proven proliferative lupus glomerulonephritis (World Health organization class III and IV), and (5) proteinuria ≥500 mg in 24 h. Patients who had abnormal menstruation, or had taken prednisolone ≥15 mg/day (or equivalent) or CYC during the previous month were excluded (except using glucocorticoids for a maximum of 10 days before referral). Other exclusion criteria were pregnancy, malignancy, gynecological disease, diabetes mellitus, and patients who received methylprednisolone pulse therapy.
Immunosuppressive treatment and study protocol One hundred thirteen patients were assigned to the shortinterval lower-dose (SILD) group and received 12 fortnightly IV CYC pulses at a fixed dose of 400 mg; subsequent doses were decreased to 400 mg monthly for 6 months as well. On the other hand, 112 patients were assigned to the high-dose (HD) group and received 8 IV CYC pulses within a year (6 monthly pulses followed by 2 quarterly pulses). The former 6 pulses were at a dose of 500 mg/m 2 of body surface area, and the subsequent doses were increased by 250 mg according to the white blood cell (WBC) count nadir measured on day 14 [7] , up to a maximum of 1,500 mg per pulse. The initial dosage of prednisone (or equivalent) for all the patients was 0.5∼1 mg/kg per day for 4 weeks. After 4 weeks, the dosage of prednisolone was tapered by 2.5 mg every 2 weeks. Low-dose prednisone therapy (5∼7.5 mg of prednisone per day) was maintained in the remaining time.
Patients with hypertension were treated primarily with angiotensin-converting enzyme inhibitors (ACEI) unless contraindicated.
Efficacy and safety assessments
The primary end point was the remission of LN (includes complete and partial remission) at the 6th month. A complete remission (CR) was defined as a value for urinary protein excretion that was less than 0.3 g per 24 h, with normal urinary sediment and serum albumin (ALB) concentration, and values for both serum creatinine (sCr) and creatinine clearance that were 15 % or less above the baseline values. A partial remission (PR) was defined as a value for urinary protein excretion that was 0.3-2.9 g per 24 h, with an ALB concentration of at least 3.0 g/dL and stable renal function.
Treatment failure was defined as a value for urinary protein excretion that remained at or above 3 g per 24 h, or a value of 0.3-2.9 g per 24 h but with an ALB concentration of less than 3.0 g/dL, an increase in the sCr concentration greater than or equal to 0.6 mg/dL (50 μmol/ L), or a value for creatinine clearance that was more than 15 % above the baseline value, or the discontinuation of treatment due to side effects [8] .
Secondary end point included death, elevation of systemic lupus erythematosus disease activity index (SLEDAI) score, commencement of permanent dialysis and kidney transplantation.
All patients were to be seen at regular intervals of 3 months or more frequently if medically indicated. Complete history inquiry, physical examination, and routine laboratory tests [complete blood count, erythrocyte sedimentation rate (ESR), sCr, ALB, 24-h urinary protein, immunoglobulin (Ig), C3, C4, ANA, and anti-double-stranded DNA (dsDNA) antibody] were performed and collected at the 6th month and at the end of clinical trial.
A nadir of WBC count lower than 3.0×10 9 /L or a WBC count that could not recover after a month of symptomatic treatment would be an indication to withdraw a patient from the study to ensure the safety of the patient. What is more, the patients would be withdrawn if their liver function indices were twofold higher than the normal range during the trial and unrecovered after symptomatic treatment for 1 month. Anti-infective drugs were administered when infection occurred.
Statistical analysis
Consecutive data were compared within and between the two groups by repeated measures analysis of variance. Unpaired t tests or Mann-Whitney U tests were used for between-group comparisons, and paired t test was used for within-group comparisons. Categorical groups were compared by chisquare test and Fisher's exact test. Statistical analyses were performed with the use of SPSS for Windows 16.0. Statistical significance was indicated by two-sided P values <0.05.
Results

Baseline data and treatment
One hundred thirteen patients were assigned to the SILD IV CYC group and 112 to the HD IV CYC group. The clinical characteristics of patients between the two groups did not differ significantly at baseline ( Table 1) .
As shown in Fig. 1 , six patients of the SILD group dropped from the trial for the following reasons: lost to follow-up (n= 2), patient's decision (n=1), lack of efficiency (n=1), and toxic effects (n=2). Besides, five patients of the HD group dropped from the trial for the following reasons: end-stage renal failure (n=1), toxic effects (n=3), and serum creatinine (sCr) continuing to be higher than normal (n=1). Patients who did not achieve 3-month regular follow-up were not analyzed.
Outcome of treatment
Remission occurred in 79.4 % of patients (85/107) in the SILD group and 84 (78.5 %) in the HD group (P=0.867). The incidences of CR or PR were similar in the two groups ( Table 2 ). The mean time of CR was 4.61±2.80 months for the SILD group and 4.00±2.89 months for the HD group (P= 0.633).
The proportion of patients with high serum anti-dsDNA antibody concentrations was reduced from 58.4 to 23.0 and 12.4 % after 6 and 12 months of treatment in the SILD group.
In the HD group, the proportion was reduced from 54.5 to 18.8 and 14.3 %.
Serial values for SLEDAI score, ALB and sCr concentrations, and urinary protein excretion per 24 h were similar in both groups (Fig. 2) . The SLEDAI score decreased from 15.5 ±7.1 at baseline to 4.4±2.8 at 6 months in the SILD group (95 % confidence interval (CI), 7.7-12.9; P=0.000), and from 14.2±5.9 at baseline to 5.0±4.0 at 6 months (95 % CI, 6.9-10.2; P=0.000) in the HD group, respectively. From baseline to 6 months, urinary protein excretion per 24 h decreased from 2.68±2.41 to 0.75±0.82 g in the SILD group and from 3.23± 2.90 to 1.1±1.8 g in the HD group. The ALB concentration increased from a baseline of 29.4±4.7 to 40.3±3.6 g/L at 6 months in the SILD group and from 27.5±6.4 to 37.2± 6.4 g/L in the HD group. There was no significant difference in the serum creatinine between groups at the end of 6 months (mean serum creatinine was 57.3±16.1 and 74.8±27.5μmol/L in the SILD and HD groups, respectively). At 12 months, SLEDAI score, 24 h urinary Fig. 2 Mean (±SD) SLEDAI, urinary protein excretion, serum albumin, and serum creatinine in patients with lupus nephritis. The mean SLEDAI was significantly lower than the baseline value after 6 months of therapy in the HD group and in the SILD group, and it remained significantly lower after 12 months in the two groups. Urinary protein excretion was significantly lower than the baseline value after 6 months of therapy in the SILD group and in the HD group, and it remained significantly lower after 12 months in the two groups. The mean serum albumin concentration was significantly higher than the baseline value after 6 and 12 months in both groups. *P<0.05 vs baseline value protein excretion, and ALB were sustained. There was no statistical difference between the two groups regarding the concentration of sCr at the end of trial.
Other indicators of SLE and LN activity had some improvement including the serum concentration of C3 and C4 within groups. However, there was no significant difference of these parameters between the two groups (Table 3) .
There was one end-stage renal failure (ESRF) in each group. One patient in the SILD group developed ESRF. The patient started hemodialysis 4 months after recruitment. The other from the HD group went into ESRF 2 months after recruitment and dropped from the clinical trial.
Adverse events
All adverse events occurring between study inclusion and last follow-up visit were recorded (Table 4) . Menstrual cycle disturbances occurred in both regimens. At month 12, 11.5 % of patients in the SILD group had menstrual disturbance, compared with 28.6 % in the HD group (P=0.001). The gastrointestinal adverse effects (nausea or vomiting) occurred more frequently in the HD group than in the SILD group (26.8 vs 5.3 %; P=0.000). Leukopenia (defined as WBC count of less than 3.5×10 9 /L) occurred more frequently in the HD group (19.8 %) compared with the SILD group (9.7 %; P=0.036). One patient in the HD group withdrew from the study for continuing leukopenia; the others recovered to the normal level in a short period of time.
Infectious events included herpes zoster, pneumonia, urinary tract infection, upper respiratory tract infection, and so on. The incidence of infections were 17.7 % of the SILD group and 22.3 % of the HD group (P=0.386). The rate of pneumonia was higher in the HD group, but the differences did not reach statistical significance. In addition, the occurrence of urinary infection and herpes zoster of these two groups were similar with each other (Table 4 ). All infected patients were convalesced after the treatment of antibiotic or antiviral agents, so there was no influence on the therapy of LN.
As indicated in Table 4 , one patient in the HD group and one patient in the SILD group had progressed to ESRF and currently undergoing dialysis. Two patients, also one in the HD group and one in the SILD group, had been censored because of doubling of sCr level.
Discussion
We report a prospective 1-year follow-up study comparing the efficacy and safety of two IV CYC regimens. In this patient population, we confirm that the efficacy and kinetics of the initial response between the two groups appear to be comparable. Side effects were less common in the SILD group. Recently, there has been still a lot of controversy over the best IV CYC regimen for patients with SLE. Though high-dose IV CYC in combination with glucocorticoids viewed as the most effective immunosuppressive medication for LN, no final conclusion has yet been reached on this matter so far. With development of further research into this issue, several investigators have raised concerns about the high-dose CYC regimen for the treatment of SLE, especially the risks of infection and ovarian failure [9, 10] . Meanwhile, other researchers put forward a question on whether the patients with mild damage should use this regimen or not.
On the other hand, the regimen of low-dose IV CYC has become more and more popular in recent years. Many studies have come to the conclusion that the effect of the low-dose therapy is comparable with the recommended high-dose regimen and with a considerably low incidence of infections [3, [11] [12] [13] . However, our results showed that the incidence of infections between the two groups had no notable differences. As indicated in Fig. 2 , the level of 24-h urinary protein in both groups experienced a similar decrease after 1 year of treatment. But we also observed that there were cases in both groups whose 24-h urinary protein were not reduced to the SLEDAI systemic lupus erythematosus disease activity a Change at 6 months from baseline value b P value not significant for comparison between groups normal range, in spite of an obvious decrease after the treatment of 6 months. It revealed that the treatment duration of 6 months was not enough to control renal damage efficiently in neither of the groups. The relapse rate was high when CYC were ceased after 6 months of treatment reported by other studies. In our study, although we cut down the dose of CYC to 400 mg monthly after 6 months, the SILD regimen was still very effective in reducing the proteinuria and improving the renal function. In the meantime, the positive rate of antidsDNA antibody was reduced to 23.0 % (SILD group) and 18.8 % (HD group) after 6 months of therapy. After 1 year of treatment, the positive rate of anti-dsDNA antibody was continuously decreased to 12.4 % (SILD group) and 14.3 % (HD group), respectively. From our data, the SILD regimen seems to be more efficient in reducing the positive rate of antidsDNA antibody than the HD regimen. Many studies have come up with several different regimens for remission-maintaining treatment followed by azathioprine (AZA), mycophenolate mofetil (MMF), and oral or IV CYC [5, [14] [15] [16] . And the MMF regimen seems to be the most effective one; however, there would be limitations in longterm using of MMF because of its high expense in developing countries. Based on our daily clinical observations, we concluded that it was essential for the SLE patients to receive an IV CYC regimen intermittently with better effect and lower relapse rate for more than 1 year, especially for those severe LN patients with dissatisfactory pathology type [17] [18] [19] [20] [21] [22] [23] . Therefore, we are planning to follow and administer these patients 400 mg every 2 or 3 months in order to reach the better effect, lower relapse rate, as well as to reduce the dose of prednisone as early as possible.
CYC is a cyclical non-specific alkylating agent, which inhibits DNA replication and initiates cell death. CYC may affect all the components of cellular and humoral immunity, and may reduce the production of immunoglobulins and the concentration of the immunoglobulins in the serum. It is very important to take into account the potential of bone marrow suppression caused by pulse therapy of CYC. In recent years, many studies have showed that CYC may cause leukopenia, thrombocytopenia, and erythropenia. The WBC count showed a saw-tooth pattern with IV CYC as it reached a nadir approximately 2 weeks following administration [24] . Our data showed that the SILD IV CYC would keep the WBC counts at relatively low levels. These findings provide strong evidence for the SILD IV CYC regimen, but we cannot infer the real changes of the lymphocyte function only owing to WBC of the peripheral blood, so further research is needed.
Gonadal toxicity remains an important issue contributing to significant physical and emotional consequences in young women patients with SLE. Studies have reported ovarian insufficiency in 10-83 % of female SLE patients treated with CYC, depending primarily on the subject's age at initiation of treatment and cumulative CYC dose [25] [26] [27] . Medeiros et al. showed that SLE patients treated with a cumulative CYC dose of greater than 10 g had a 3.2 times higher risk of developing ovarian insufficiency than patients receiving a cumulative dose lower than 10 g [28] . Our results showed that 28.6 % of patients with premature cessation of menses following high-dose CYC were consistent with previous reports. However, it was significantly lower in the SILD group. One explanation is the cumulative dose that is lower in the SILD group; another possibility is that the lower dosage in one administration may lead to lower toxicity in menstruation.
In conclusion, the efficacy of SILD IV CYC regimen in the treatment of LN is similar to that of the HD regimen, but the incidence of menstrual disturbances, gastrointestinal adverse effects, and leukopenia is much lower in the SILD IV CYC group than the standard therapeutic regimen.
